Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab

NCT05049161 is registered in ClinicalTrials.gov with GeNeuro Innovation SAS as lead sponsor.

NCT NCT05049161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05049161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab
Lead sponsor
GeNeuro Innovation SAS
Phase
Phase 2
Overall status
Terminated
Start date
August 27, 2021
Completion date
May 18, 2022
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis